Advanced Healthcare Materials · 2018 · 39 citations · 42 references
MedicineImmunologyPharmacologyAutoimmunityImmunopharmacologyImmunotherapyCell-based ImmunotherapyDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapyInsulin TherapyPancreatic HormonesAdoptive ImmunotherapyBiodegradable Delivery PlatformsBiodegradable Delivery SystemsPeptide-based ImmunomodulationPolymeric MicroparticlesTolerogenic Dendritic CellsTolerogenic ImmunotherapyType 1 Diabetes Pharmacotherapy
Abstract Type 1 diabetes (T1D) is a common autoimmune disease with no cure. T1D subjects are dependent on daily exogenous insulin administration, due to the loss of functional insulin‐producing β cells. Needed are immunotherapies that prevent and/or treat T1D. One approach of immunotherapy is to administer an autoantigen to selectively tolerize diabetogenic effector T cells without global immunosuppression. To date, however, strategies of antigen‐specific immunotherapy are largely ineffective in the clinic. Using an antigen‐specific approach, a biodegradable polymeric delivery vehicle, acetalated dextran microparticles (Ace‐DEX MPs), is applied and T1D development is prevented through coadministration of the immunosuppressant rapamycin and the diabetogenic peptide P31 (Rapa/P31/MPs), via alterations of both innate and adaptive immunity. Ex vivo, adoptively transferred CD4 + T cells exhibit reduced proliferation and an increased ratio of FoxP3 + to IFNγ + T cells. In vitro analysis indicates dendritic cells exhibit a less mature phenotype following coculture with Rapa/P31/MPs, which results in reduced CD4 + T cell proliferation and proinflammatory cytokine production (IFNγ and IL‐2), but promotes PD‐1 expression. Together these results demonstrate Ace‐DEX MP‐based antigen‐specific therapy effectively tolerizes diabetogenic CD4 + T cells to prevent T1D, thereby demonstrating one of the first successful attempts of T1D prevention using a single‐formulation particulate delivery platform.
42
Nanoparticles target distinct dendritic cell populations according to their size
Vania Manolova, Anna Flace, Monika Bauer et al. · European Journal of Immunology · 2008 · 1.3K citations · Full text
Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes
Bart Keymeulen, Evy Vandemeulebroucke, Anette G. Ziegler et al. · New England Journal of Medicine · 2005 · 1.1K citations · Full text
Medicine, Endocrinology, Immunology +17
Kevan C. Herold, Stephen E. Gitelman, Umesh Masharani et al. · Diabetes · 2005 · 636 citations · Full text